about
Imaging microscopic pigment chemistry in conjunctival melanocytic lesions using pump-probe laser microscopy.Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.High levels of Hdmx promote cell growth in a subset of uveal melanomas.Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.Primary orbital melanoma in association with cellular blue nevusThe impact of selected factors on early diagnosis of multiple primary cancers in patients with uveal melanoma.Malignancies of the eyelid: a review of primary and metastatic cancers.Transhepatic therapies for metastatic uveal melanoma.Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.Advances in the management of conjunctival melanoma.Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma.(18)F-FDG PET-CT for Staging of Conjunctival Melanoma.Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.Preliminary results of contrast-enhanced sonography in the evaluation of the response of uveal melanoma to gamma-knife radiosurgery.Conjunctival Melanoma: A New Clinical and Therapeutical ApproachGiant Orbital Melanoma in a Heroin Abuser.FGF2 promotes metastasis of uveal melanoma cells via store-operated calcium entry.Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma.Primary Orbital Melanoma: Presentation, Treatment, and Long-term Outcomes for 13 Patients.Evaluation of dose enhancement in presence of gold nanoparticles in eye brachytherapy by 103Pd source.Transretinal uveal melanoma biopsy with 25-gauge vitrectomy system.
P2860
Q34996843-DDAADB6F-BD46-450D-894E-42BBC940C813Q36100681-51D41605-6B20-48CF-8010-79EDFD593109Q36206473-7C9F9AB3-8B39-4ED7-993B-CA582B8741A3Q36946632-A34B3A76-217A-4906-A3FD-5B278BF037EFQ37395432-244CFB4E-5153-42C9-9692-6F20BB5BB080Q37601889-14FD3DCE-FEAA-4180-8FB3-E95C0397F7CEQ38122749-6CD2B427-27A2-4150-A7FF-E487AF7A7C18Q38179345-68BA13F5-2FF9-42D5-ACEF-5CA76D8B70C1Q38186120-46569E06-4D42-46D9-8781-51ABD1D3A3E7Q38193210-C5EDB94E-5ED9-49A3-9C4A-04587F7F31D3Q38201794-B478552D-D03A-4E39-8820-0454DA7B7F4EQ38870401-E2341731-21DF-4B55-867B-48E27394E3EDQ39145837-A976AC6F-6D30-40F0-A48C-EFF179B71A6AQ39315926-1A59DFBF-114F-477A-AB3F-770192F39BA9Q39364421-1E6FF0A3-6ED1-496C-A111-19D0EAD57AB3Q39396223-FAD54A3E-7BAB-4C3F-A69C-D518974CBA2CQ41372762-22A2FC9B-A9C5-444B-8751-4C37B91F999AQ41844130-ED54643F-1D8A-4119-9C4D-B8E91E35C23DQ42256468-C02C3263-EB6E-4ED2-9A63-25C593D98629Q47146481-308803E5-B3C2-4D38-8C26-01B46F3959ABQ47620145-A3C019F5-6E58-44F7-A635-DA7E05D1EBB8Q50074930-78CAC181-4547-4672-BEAB-787B791948EBQ50644112-9E396A4A-622C-4986-96CE-A6EA0A5DEE13Q53224123-9CEBEC5F-B732-473E-B9C6-1A6E9D5DDCBF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ocular melanoma: relatively rare but requiring respect.
@en
Ocular melanoma: relatively rare but requiring respect.
@nl
type
label
Ocular melanoma: relatively rare but requiring respect.
@en
Ocular melanoma: relatively rare but requiring respect.
@nl
prefLabel
Ocular melanoma: relatively rare but requiring respect.
@en
Ocular melanoma: relatively rare but requiring respect.
@nl
P1476
Ocular melanoma: relatively rare but requiring respect.
@en
P2093
Carol L Shields
Jerry A Shields
P304
P356
10.1016/J.CLINDERMATOL.2008.09.010
P577
2009-01-01T00:00:00Z